design: Single-cell transcriptomic profiling of 16 synovial sarcoma tumors
library_construction_protocol: The study included 16 male and female patients aged 19-77, with the diagnosis of primary or recurring SyS (13 monophasic and 3 biphasic cases) and with or without neoadjuvant treatment. Surgically removed tumor samples (20-25 mg) were used to perform scRNA-seq. The study was conducted in accordance with the Declaration of Helsinki and approved by The Ethics Committee of N.N. Blokhin National Medical Research Center of Oncology (27 October 2020; Approval number: 2020-42). Informed consent for the study and the future publication has been obtained from the patients.   The fixation and dissociation of tumor samples were performed according to the Tissue Fixation & Dissociation Protocol for Chromium Fixed RNA Profiling (10x Genomics, USA) using the DCS-400 single cell suspension dissociator and the Tumor Enzymatic Dissociation Kit  (RWD Life Science, China). After the dissociation, the cells were counted with acridine orange/propidium iodide staining buffer (Logos Bioscience, Korea) on the LUNA-FL Dual Fluorescence Cell Counter (Logos Bioscience, Korea). The dissociated cell suspension was stored at –80℃ with 275 µl of 50% glycerol (Central Drug House Ltd, India) and 100 µl of Enhancer solution (10x Genomics, USA). Before the Chromium Fixed RNA Profiling, cells were thawed, centrifuged, resuspended in 0.5x PBS (Diagene, Switzerland) with 0.02% BSA (Dia-M, Russia), and counted again. For each SyS tumor sample, 8000 cells were taken into the scRNA-seq.  The single-cell transcriptomic libraries were constructed in accordance with the Chromium Fixed RNA Protocol using  the Chromium iX/X controller (10x Genomics, USA). The PCR amplification was done on the QuantGene 9600 machine (Bioer Technology, China). 